CXCL13 and breast carcinoma: Furthermore, the CXCL13 single gene was strongly associated with a higher rate of pCR, particularly in the HER2+ subtype in a cohort diagnosed with breast cancer and treated with neoadjuvant chemotherapy (n = 996) supporting the hypothesis that the presence of CXCL13-producing Tfh cells may induce antitumor immune responses associated with improved outcome.